Innovations in treating acute graft-versus-host disease: a review of preclinical targets and strategies

Haoliang Duan Yuhua Ru Jia Chen a Institute of Blood and Marrow Transplantation,Collaborative Innovation Center of Hematology,Soochow University,Suzhou,Chinab Suzhou Medical College,Soochow University,Suzhou,Chinac National Clinical Research Center for Hematologic Diseases,Jiangsu Institute of Hematology,The First Affiliated Hospital of Soochow University,Suzhou,China

DOI: https://doi.org/10.1080/14728222.2024.2405091

IF: 6.797

2024-09-21

Expert Opinion on Therapeutic Targets

Abstract:Introduction Acute graft-versus-host disease (aGVHD) is a major complication of post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) that severely impacts patient survival and quality of life. Despite advancements in standard care, therapeutic outcomes remain suboptimal, necessitating the exploration of innovative strategies.

pharmacology & pharmacy